Hikma Pharmaceuticals PLC (LSE:HIK)
£ 18.31 0.3 (1.67%) Market Cap: 4.06 Bil Enterprise Value: 4.80 Bil PE Ratio: 27.57 PB Ratio: 2.36 GF Score: 90/100

Full Year 2018 Hikma Pharmaceuticals PLC Earnings Call Transcript

Mar 13, 2019 / 09:30AM GMT
Release Date Price: £15.85 (-4.29%)
Sigurdur Oli Olafsson
Hikma Pharmaceuticals PLC - CEO & Executive Director

So good morning, everyone. Welcome. Thanks for joining us this morning. I know a few more faces than a year ago when I first joined the company, so to introduce myself, I'm Siggi Olafsson, the CEO of Hikma. With me today is Khalid Nabilsi, the CFO; part of the executive group of Hikma; and of course, the Investor Relation. Joining us for Q&A will be Said Darwazah, the Executive Chairman, so he will join us for the Q&A after the presentation.

So at the Capital Market Day, we presented the strategy for the group, and what I'm going to do is to give you an update to that strategy where we are, how we are progressing, then I will hand it over to Khalid to provide an overview of the financial performance of the group. And then, of course, we will open it up for questions.

So turning to Slide 3, this is our group highlights. The group has delivered a strong performance in 2018, with the revenue and profitability significant above the guidance that we set at this time last year. Across the group, we have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot